分子量:12.8 kDa

纯度:>95% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the ActiveMax Human IL-15 by the LAL method.

Buffer:PBS, pH7.4

生物活性:The bio-activity was determined by dose-dependent stimulation of the proliferation of mouse CTLL-2 cells. The ED50 < 0.5 ng/mL, corresponding to a specific activity of >2X106 Unit/mg.

产品特性:ActiveMax Human IL-15 contains no "tag", and has a calculated MW of 12.8 kDa. The predicted N-terminus is Asn 49. The reducing (R) protein migrates as 13 kDa in SDS-PAGE .

产品背景:Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.